Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

NCT02519036 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: ISIS 443139 10 mg
DRUG: ISIS 443139 30 mg
DRUG: ISIS 443139 60 mg
DRUG: ISIS 443139 90 mg
DRUG: ISIS 443139 120 mg
OTHER: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.